Literature DB >> 3788398

The Hartmann procedure for the treatment of colorectal emergencies.

O A Hulkko, S T Laitinen, K A Haukipuro, M J Ståhlberg, T S Juvonen, M I Kairaluoma.   

Abstract

A total of 80 patients with colorectal emergencies were treated by the Hartmann procedure at the Oulu University Central Hospital during the years 1973-1984. The median age of the patients was 65 (18-81) years. The operative indications were: diverticular disease (n = 26), cancer (n = 21), stercoraceous perforation (n = 9), vascular accident (n = 5), radiation damage (n = 4) and miscellaneous (n = 11). 13 patients (16.3%) died after a median of 8 (1-33) days, mostly due to organ failure. 44 of the surviving 67 patients (65.7%) had postoperative complications. Intestinal continuity was restored in 34 patients (42.5%) after a median of 139 (65-794) days. Two patients (5.6%) died after the reconstruction. The permanency of the stoma in half of the surviving patients and the technical difficulties encountered in stoma closure are disadvantages attached to the Hartmann procedure which are sufficiently serious that alternative operative methods should always be considered.

Entities:  

Mesh:

Year:  1986        PMID: 3788398

Source DB:  PubMed          Journal:  Acta Chir Scand        ISSN: 0001-5482


  3 in total

1.  HARTMANN'S PROCEDURE REVISITED.

Authors:  R P Choubey; P K Patnaik; A K Sharma; S Kapoor
Journal:  Med J Armed Forces India       Date:  2011-07-21

2.  Operative strategies for diverticular peritonitis: a decision analysis between primary resection and anastomosis versus Hartmann's procedures.

Authors:  Vasilis A Constantinides; Alexander Heriot; Feza Remzi; Ara Darzi; Asha Senapati; Victor W Fazio; Paris P Tekkis
Journal:  Ann Surg       Date:  2007-01       Impact factor: 12.969

3.  Surgical management of the septic complications of diverticular disease.

Authors:  A L Khan; A K Ah-See; T J Crofts; S D Heys; O Eremin
Journal:  Ann R Coll Surg Engl       Date:  1995-01       Impact factor: 1.891

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.